Nitric oxide Inhibitors
1 drugsAbout Nitric oxide
Nitric oxide (NO) is a simple molecule involved in various biological processes. It plays a crucial role in key physiological functions, making it a potential drug target.
Currently, there is no genetic evidence directly linking nitric oxide to specific diseases. However, pharmaceuticals have been developed to modulate its activity, primarily in cardiovascular health.
BIDIL is the only FDA-approved drug targeting nitric oxide, formulated as a small molecule. AZURITY is the sole company with an approved drug in this area.
Top Nitric oxide Drugs
AZURITY is the only company with an approved drug targeting nitric oxide.
Low competition suggests an opportunity for new entrants, but also highlights potential challenges.
Nitric oxide Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Nitric oxide, using small molecule modality.
Explore alternative modalities like biologics to differentiate from existing therapies.
Nitric oxide Clinical Trials 7 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Nitric oxide. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 | 100% |
| Phase 2 | 3 | 3 | 0 | 0 | 100% |
| Phase 3 | 2 | 2 | 0 | 0 | 100% |
| Phase 4 | 1 | 0 | 0 | 1 | - |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Nitric oxide Drug Approval Timeline (2005 - 2005)
The first and most recent drug approval was BIDIL in 2005.
The lack of recent approvals indicates a potentially saturated market or challenges in developing new therapies.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 7 (1 company)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Nitric oxide. A trial counts if an approved drug acting on Nitric oxide is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.